China Focus: Stricter regulations, sports nutrition, and hemp sales growth among our latest China stories
Hemp health products boost revenue by 50% at China Health Industries Holdings: Exclusive interview
China Health Industries Holdings saw its revenue jump by 50% year-on-year during the second quarter of its FY 2019, ending December 2018, on the back of strong demand for products containing hemp.
The financial results released on February 14 showed that revenue grew to US$2.7m from US$1.8m from October and December 2017 to October and December 2018.
In an interview with NutraIngredients-Asia, Xin Sun, CEO of the Heilongjiang-based firm, pointed out that revenue growth was fuelled by sales of its new hemp derivative products, including health foods and cosmetics.
Sports nutrition success for Sirio Pharma as firm receives China licence approval
Chinese firm Sirio Pharma has had its sports nutrition product licence approved in China, signalling new expansion opportunities for the company and its clients in the country's growing market.
The nutraceutical contract manufacturer announced that this approval allowed it to produce sports nutrition food in China, and it could therefore add special ingredients into its products.
This covers six functional classes: protein supplementary, speed and power, endurance, energy control, energy supplementary, and post-exercise recovery.
China today, the world tomorrow: Korean brand plans global presence for signature red ginseng product
South Korean organic produce distributor Ewha Company is planning to go international with its food brand Nature Food's signature red ginseng product, having China firmly in its sights.
Called Chong Kun Dang 6-Year-Old Red Ginseng Gold, the product is said to be suitable for adults in general and seniors in particular.
Red ginseng's multiple health benefits include immune support, physical stamina support, antioxidant properties, cognitive enhancement, improvement of blood circulation, improvement of respiratory and heart health, and fatigue relief.
China's 100-day health food crackdown: 300 cases valued at US$6.7m in first wave of action
At least 300 cases worth roughly US$6.7m (RMB45m) have been identified since China launched a '100-day operation' to stem illegal and unethical practices across the nation's health food and supplement industry.
The operation involves authorities from 13 government units, and is targeted at individuals and firms involved in putting up fake advertisements, manufacturing and selling counterfeits, and other illegal and deceptive actions that disrupt the health food market.
In the past two and a half weeks, the operation has brought to light at least 300 cases of illegal activities amounting to US$6.7m (RMB45m), China's State Administration for Market Regulation (SAMR) announced during a press conference on January 30.
Sampling and on-site inspection of infant formula powder pending registration approval to increase: China regulator
China will tighten its inspection of infant formula products that are pending registration approval by conducting more sample testing and on-site inspection.
The State Administration for Market Regulation (SAMR) Department of Special Food Safety Supervision's deputy head Ma Fuxiang said so during the 2nd edition of the China Dairy Quality Annual meeting, held on January 21.
Ma said that the SAMR took a serious view of the registration process of infant formula powder. Product safety and the scientific evidence presented are key areas of focus.
